NEW YORK (GenomeWeb) – Albany Molecular Research (AMRI) and PerkinElmer are collaborating to provide drug discovery infrastructure and services in AMRI's newly launched drug discovery center.
The new AMRI center is part of the Buffalo Medical Innovation and Commercialization Hub (BMIC), a public-private pharmaceutical research and development initiative in Buffalo, New York. The Hub is a collaborative effort that involves SUNY Polytechnic Institute and the State of New York, AMRI, and other industry partners that provide services, platforms, and expertise needed to support drug development projects in academia and industry.
As a result of its collaboration with PerkinElmer, scientists at the BMIC hub will have access to AMRI's chemistry and biology expertise, and they will have access PerkinElmer's informatics technologies and high-content screening capabilities, as well as its cellular imaging and analytics instruments. PerkinElmer will also provide technical and informatics experts to facilitate technological and drug discovery innovations.
"We are pleased to have the opportunity to deliver the platforms, informatics technologies and services to AMRI for its new center of excellence for drug discovery and translational research," Jim Corbett, PerkinElmer's president, human health, said in a statement. "We look forward to supporting the BMIC's expansion by working closely with additional companies that establish lab facilities at this site."